Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

New Data Demonstrate Potential For Early Detection Of Alzheimer's Disease Using New Diagnostic Technology, Which Could Lead To Improved Treatment
Data published in the June issue of the Journal of Alzheimer"s Disease demonstrated that minimally-invasive biospectroscopy was able to identify changes in oxidative stress (OS) levels in blood plasma, which may prove to be a useful biomarker in the early detection of Alzheimer"s disease. There is currently no accepted laboratory test for diagnosing Alzheimer"s disease.
generic viagra online
UCSF Researchers Help Crack Parasite Genome, Identify Drug Leads
Two UCSF research papers this week are marking major breakthroughs in the effort to tackle schistosomiasis (bilharzia), a tropical disease that infects more than 200 million people worldwide and causes long-term debilitating illness and occasional paralysis or death.
News of the day
'Super-Recognizers,' With Extraordinary Face Recognition Ability, Never Forget A Face
Some people say they never forget a face, a claim now bolstered by psychologists at Harvard University who"ve discovered a group they call "super-recognizers": those who can easily recognize someone they met in passing, even many years later.
Mental Health

Learning More About The Placebo Effect

In this trial, a sample of alcohol-dependent patients received naltrexone, acamprosate or placebo for 12 weeks. While there were no differences in outcomes between treatment groups, those who believed they had been taking active medication consumed fewer alcoholic drinks and reported less alcohol dependence and cravings. That is, irrespective of actual treatment, perceived medication allocation predicted health outcomes. Double-blind placebo-controlled trials are intended to control for the impact of expectancy on outcomes. Whether they always achieve this is, however, questionable. Reanalysis of a clinical trial of naltrexone and acamprosate for alcohol dependence investigated this issue further. In this trial, 169 alcohol-dependent patients received naltrexone, acamprosate or placebo for 12 weeks. In addition to being assessed on various indices of alcohol dependence, they were asked whether they believed they received active medication or placebo. While there were no differences in outcomes between treatment groups, those who believed they had been taking active medication consumed fewer alcoholic drinks and reported less alcohol dependence and cravings. That is, irrespective of actual treatment, perceived medication allocation predicted health outcomes. These results highlight the differences between treatment administration in clinical trials and standard medical practice, a discrepancy that may sometimes decrease the validity of these types of trials. Psychotherapy and Psychosomatics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009